Evidence map›Paper›PMID 36459528›Full record

ArticlePloS one2022

Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer.

Takaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, Yoko Tsukita, Rei Umezawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Takaya YamamotoDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0003-3562-1037
Yoshiyuki KatsutaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kiyokazu SatoDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoko TsukitaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Rei UmezawaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Noriyoshi TakahashiDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0002-7653-0046
Yu SuzukiDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuya TakedaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0002-7354-4063
Keita KishidaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
So OmataDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ryota SaitoDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Noriyuki KadoyaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Keiichi JinguDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced lung toxicity and the decline in pulmonary function after radiotherapy. MATERIALS AND

methodsProtocol-specified examinations, including 4-D CT, laboratory tests, pulmonary function tests (PFTs) and body composition measurements, were performed before SRT and at 1 month, 4 months and 12 months after stereotactic radiotherapy. Longitudinal differences were tested by using repeated-measures analysis of variance. Correlations were examined by using the Pearson product-moment correlation coefficient (r).

resultsSixteen patients were analyzed in this study. During a median follow-up period of 26.6 months, grade 1 and 2 lung toxicity occurred in 11 patients and 1 patient, respectively. The mean Hounsfield units (HU) and standard deviation (SD) of the whole lung, as well as sialylated carbohydrate antigen KL-6 (KL-6) and surfactant protein-D (SP-D), peaked at 4 months after radiotherapy (p = 0.11, p<0.01, p = 0.04 and p<0.01, respectively). At 4 months, lung V20 Gy (%) and V40 Gy (%) were correlated with changes in SP-D, whereas changes in the mean HU of the lung were related to body mass index and lean body mass index (r = 0.54, p = 0.02; r = 0.57, p = 0.01; r = 0.69, p<0.01; and r = 0.69, p<0.01, respectively). The parameters of PFTs gradually declined over time. When regarding the change in PFTs from pretreatment to 12 months, lung V5 Gy (cc) showed significant correlations with diffusion capacity for carbon monoxide (DLCO), DLCO/alveolar volume and the relative change in DLCO (r = -0.72, p<0.01; r = -0.73, p<0.01; and r = -0.63, p = 0.01, respectively).

conclusionsThe results indicated that some parameters peaked at 4 months, but PFTs were the lowest at 12 months. Significant correlations between lung V5 Gy (cc) and changes in DLCO and DLCO/alveolar volume were observed.

Indexed as

Lung NeoplasmsRadiation InjuriesRadiosurgeryHumansLungProspective StudiesPulmonary Surfactant-Associated Protein DPulmonary Surfactant-Associated Protein D

Identifiers

PMID36459528
PMCPMC9718403
OpenAlexW4310576791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.